JAPANESE RED CEDAR ALLERGY
ASP4070 (formerly known as JRC-LAMP-vax) is a groundbreaking investigational vaccine for treating patients suffering with allergies to Japanese cedar pollen, one of the most potent and problematic pollen allergies in the world. Astellas Pharmaceuticals, Inc is leading the clinical development of ASP4070 in Japan, where it has exclusive rights for commercial development, marketing and sales.
The Japanese red cedar tree is a national scourge but also a cultural symbol in Japan. It is estimated that 25% of the Japanese population, more than 25 million individuals, are allergic to Japanese red cedar pollen .
ASP4070™ – ADDRESSING AN ALLERGY THAT AFFECTS OVER 25 MILLION JAPANESE
ASP4070TM Vaccine Key Features
- ASP4070 is a vaccine intended to treat patients with rhino-conjunctivitis caused by allergic reaction to red cedar pollen
- First immunotherapy to treat allergy that does not expose patient to free allergen
- ITI’s LAMP-vax vaccine allergy therapy is expected to require only 4 shots, not 100 or more often required for traditional, extract-based immunotherapy
This vaccine has been designed and validated in two species and is now being tested in humans. ITI has completed Phase 1A and 1B clinical trials for ASP4070, a LAMP-based vaccine for Japanese red cedar. The clinical results in allergic and non-allergic Japanese patients were favorable and strongly support further development of ASP4070.
For more information please contact:
|Immunomic Therapeutics, Inc.|
|15010 Broschart Road,
Rockville, MD 20850